HDAC9 and cancer: This suggests that hyper-acetylation caused by HDAC inhibitors is not indispensable part for HDAC inhibitor-induced cell death, implying that normal cells, not like cancer cells, may have their own resistant system to protect cells from apoptosis in response to HDAC inhibitors.